DE68921436D1 - Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt. - Google Patents

Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.

Info

Publication number
DE68921436D1
DE68921436D1 DE68921436T DE68921436T DE68921436D1 DE 68921436 D1 DE68921436 D1 DE 68921436D1 DE 68921436 T DE68921436 T DE 68921436T DE 68921436 T DE68921436 T DE 68921436T DE 68921436 D1 DE68921436 D1 DE 68921436D1
Authority
DE
Germany
Prior art keywords
cataracts
treatment
carboxylic acids
aliphatic
carbons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68921436T
Other languages
English (en)
Other versions
DE68921436T2 (de
Inventor
William H Garner
Larry A Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE68921436D1 publication Critical patent/DE68921436D1/de
Application granted granted Critical
Publication of DE68921436T2 publication Critical patent/DE68921436T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
DE68921436T 1988-12-09 1989-12-11 Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt. Expired - Fee Related DE68921436T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28276788A 1988-12-09 1988-12-09

Publications (2)

Publication Number Publication Date
DE68921436D1 true DE68921436D1 (de) 1995-04-06
DE68921436T2 DE68921436T2 (de) 1995-08-10

Family

ID=23083041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921436T Expired - Fee Related DE68921436T2 (de) 1988-12-09 1989-12-11 Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.

Country Status (6)

Country Link
US (1) US5399573A (de)
EP (1) EP0373002B1 (de)
JP (1) JPH02202818A (de)
AT (1) ATE119038T1 (de)
DE (1) DE68921436T2 (de)
ES (1) ES2068253T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0715853A1 (de) * 1991-01-10 1996-06-12 Transcend Therapeutics, Inc. Verwendung von Glutathionester zur Behandlung von Lungenerkrankungen
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
US20030130324A1 (en) * 1993-11-19 2003-07-10 Johnston W. Mcavoy Method for preventing or controlling cataract
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5925658A (en) * 1995-03-02 1999-07-20 Sankyo Company, Limited Optically active thiazolidinone derivative
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US5576278A (en) * 1995-06-07 1996-11-19 Alcon Laboratories, Inc. Stable liquid enzyme compositions and methods of use
US5686450A (en) * 1995-06-07 1997-11-11 Alcon Laboratories, Inc. Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
DK0842165T3 (da) * 1996-03-25 2001-08-06 Alcon Lab Inc Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
EP3458045B1 (de) 2016-05-18 2024-08-21 Sound Pharmaceuticals Incorporated Ebselen zur anwendung bei der behandlung der menière-krankheit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474817A (en) * 1980-02-29 1984-10-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4351826A (en) * 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4526789A (en) * 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
JPS5718615A (en) * 1980-07-07 1982-01-30 Senjiyu Seiyaku Kk Anticataract agent
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US5091421A (en) * 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors

Also Published As

Publication number Publication date
EP0373002B1 (de) 1995-03-01
EP0373002A3 (de) 1991-07-31
JPH02202818A (ja) 1990-08-10
ATE119038T1 (de) 1995-03-15
DE68921436T2 (de) 1995-08-10
EP0373002A2 (de) 1990-06-13
US5399573A (en) 1995-03-21
ES2068253T3 (es) 1995-04-16

Similar Documents

Publication Publication Date Title
DE68921436D1 (de) Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.
RU98117628A (ru) Замещенные производные тиазолидиндиона, способ их получения, фармкомпозиция
KR920000754A (ko) 환식아미드 유도체
TW206970B (de)
KR880007461A (ko) 헤테로 사이클-치환 디포스포네이트화합물 및 이의 약제학적 조성물
DK707988D0 (da) Fremgangsmaade til at haemme virus
NO833528L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenyl-cyklobutan-derivater
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
ATE110568T1 (de) Pharmazeutisches präparat zur behandlung des katarakts.
HUT50464A (en) Process for producing phenothiazin derivatives
ES8604960A1 (es) Procedimiento para preparar derivados de 1,6-naftiridina
NO169229C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-(3-alkyl-5-tert.butyl-4-hydroksyfenyl)-2-amino-6h-1,3,4-tiadiaziner
EA200000448A1 (ru) Новые полиморфные формы ципамфиллина
IE44730L (en) Phenyl piperazines
FR2539415B1 (fr) Derives de la d-2 imidazoline, leur preparation et leur application en therapeutique
ES2054829T3 (es) Antibioticos del grupo mureidomicina, su preparacion y su empleo.
FR2663026B1 (fr) Derives de [(1-arylpyrrolidin-2-yl) methyl] piperazine, leur preparation et leur application en therapeutique.
EP0369776A3 (de) Verwendung einer Zusammensetzung, die organisch gebundenes Germanium enthaltet, zur Herstellung von Arzneimitteln zur Behandlung von AIDS
ATE58141T1 (de) 1-hydroxy-5-oxo-5h-pyrido(3,2-a>-phenoxazin-3carbons|ureester.
DE69026098D1 (de) Organogermaniumderivate enthaltende Zubereitungen zur therapeutischen Verwendung
NO167382C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-hydroxy-4-(substituerte alkenyl)cyklohexancarboxylsyrer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee